CEO
DOPPL, Switzerland
Nathalie holds a MSc/PhD in Bioengineering and Biotechnology from EPFL and recently completed her eMBA at the University of Lausanne. She is the inventor, together with her co-founder Sylke Hoehnel, of two disrupting organoid technologies that she spun-out successfully over the past five years into two successful companies, SUN bioscience and DOPPL. Nathalie was selected in the Forbes’ inaugural 30 Under 30 Europe list in the category Science and Health Care and was a finalist for the Swiss Economic Forum Woman Award in 2021.
Standardized patient-derived organoids predict clinical toxicity: A case study in immuno-oncology
Wednesday, May 24, 2023
12:00 – 12:30 CET